Skip to main content
Signal8
Launch Terminal

Lycia Therapeutics, Inc. (LYCA)

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

Industry: Biotechnology

Lycia Therapeutics Inc. logo

Lycia Therapeutics Inc.

NASDAQ:LYCAHealthcare
$30.00
AH Close$26.50-11.67%vs close
Mkt Cap$1.56B
Float36.78M
O/S52.09M
Inst Own-
Dilution
Lycia Therapeutics Inc. logoNASDAQ:LYCA$30.00
FormDescription
S-8
SEC Filing
2
424B4
Prospectus
6
EFFECT
Notice of Effectiveness
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
S-1MEF
SEC Filing
3
CERT
SEC Filing
8-A12B
SEC Filing
S-1/A
Registration Statement (Amended)
6
S-1
DRS/A
5
DRS/A
SEC Filing
6
DRS
SEC Filing
5
D
06b
D
06b
D
06b

1-25 of 26